Chapter 5 Linear Quantitative Structure-Activity Relationships for the Interaction of Small Molecules with Human Cytochrome P450 Isoenzymes

Annual Reports in Computational Chemistry

Volumn 3, Issue , 2007, Pages 63-81

  Fox, Thomas ^a   Kriegl, Jan M ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548684996     PISSN: 15741400     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-1400(07)03005-8     Document Type: Review

References (145)

1. Weaver R.J. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31 (2001) 499-538
2. Wienkers L.C., and Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4 (2005) 825-833
3. Lin J.H., and Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
4. Hutzler J.M., Messing D.M., and Wienkers L.C. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?. Curr. Opin. Drug Discov. Devel. 8 (2005) 51-58
5. Kirchheiner J., and Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 1770 (2007) 489-494
6. Jenkins K.M., Angeles R., Quintos M.T., Xu R., Kassel D.B., and Rourick R.A. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J. Pharm. Biomed. Anal. 34 (2004) 989-1004
7. Ansede J.H., and Thakker D.R. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J. Pharm. Sci. 93 (2004) 239-255
8. Zlokarnik G., Grootenhuis P.D., and Watson J.B. High throughput P450 inhibition screens in early drug discovery. Drug Discov. Today 10 (2005) 1443-1450
9. de Groot M.J., and Vermeulen N.P. Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes. Drug Metab. Rev. 29 (1997) 747-799
10. de Graaf C., Vermeulen N.P., and Feenstra K.A. Cytochrome P450 in silico: an integrative modeling approach. J. Med. Chem. 48 (2005) 2725-2755
11. de Groot M.J., Kirton S.B., and Sutcliffe M.J. In silico methods for predicting ligand binding determinants of cytochromes P450. Curr. Top. Med. Chem. 4 (2004) 1803-1824
12. Maréchal J.D., and Sutcliffe M.J. Insights into drug metabolism from modelling studies of cytochrome P450-drug interactions. Curr. Top. Med. Chem. 6 (2006) 1619-1626
13. Yano J.K., Wester M.R., Schoch G.A., Griffin K.J., Stout C.D., and Johnson E.F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05 Å resolution. J. Biol. Chem. 279 (2004) 38091-38094
14. Yano J.K., Hsu M.H., Griffin K.J., Stout C.D., and Johnson E.F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol. 12 (2005) 822-823
15. Ekroos M., and Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13682-13687
16. Rowland P., Blaney F.E., Smyth M.G., Jones J.J., Leydon V.R., Oxbrow A.K., Lewis C.J., Tennant M.G., Modi S., Eggleston D.S., Chenery R.J., and Bridges A.M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281 (2006) 7614-7622
17. Ekins S., de Groot M.J., and Jones J.P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29 (2001) 936-944
18. de Groot M.J., and Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54 (2002) 367-383
19. Hansch C., Mekapati S.B., Kurup A., and Verma R.P. QSAR of cytochrome P450. Drug Metab. Rev. 36 (2004) 105-156
20. Jalaie M., Arimoto R., Gifford E., Schefzick S., and Waller C.L. Prediction of drug-like molecular properties. In: Bajorath J. (Ed). Chemoinformatics: Concepts, Methods, and Tools for Drug Discovery (2005), Humana Press, Totowa 449-520
21. Crivori P., and Poggesi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur. J. Med. Chem. 41 (2006) 795-808
22. Refsgaard H.H.F., Jensen B.F., Christensen I.T., Hagen N., and Brockhoff P.B. In silico prediction of cytochrome P450 inhibitors. Drug Dev. Res. 67 (2006) 417-429
23. Chohan K.K., Paine S.W., and Waters N.J. Quantitative structure activity relationships in drug metabolism. Curr. Top. Med. Chem. 6 (2006) 1569-1578
24. Arimoto R. Computational models for predicting interactions with cytochrome P450 enzyme. Curr. Top. Med. Chem. 6 (2006) 1609-1618
25. Verras A., Kuntz I.D., and Ortiz de Montellano P.R. Cytochrome P450 enzymes: computational approaches to substrate prediction. In: Spellmeyer D.C. (Ed). Annual reports in Computational Chemistry (2006), Elsevier, Amsterdam 171-195 Ref. Type: Serial (Book, Monograph)
26. Madden J.C., and Cronin M.T. Structure-based methods for the prediction of drug metabolism. Expert Opin. Drug Metab. Toxicol. 2 (2006) 545-557
27. Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3 (2002) 561-597
28. Kumar G.N., and Surapaneni S. Role of drug metabolism in drug discovery and development. Med. Res. Rev. 21 (2001) 397-411
29. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-580
30. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14 (2001) 611-650
31. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
32. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52 (2001) 349-355
33. de Groot M.J., Alex A.A., and Jones B.C. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem. 45 (2002) 1983-1993
34. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., and Watkins P.B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 22 (2000) 339-361
35. Smith D.A., Ackland M.J., and Jones B.C. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates. Drug Discov. Today 2 (1997) 479-486
36. Smith D.A., Ackland M.J., and Jones B.C. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: active site characteristics. Drug Discov. Today 2 (1997) 406-414
37. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., and Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37 (1998) 4137-4147
38. Hutzler J.M., and Tracy T.S. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 30 (2002) 355-362
39. Hosea N.A., Miller G.P., and Guengerich F.P. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39 (2000) 5929-5939
40. Schrag M.L., and Wienkers L.C. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391 (2001) 49-55
41. Wolff T., Distlerath L.M., Worthington M.T., Groopman J.D., Hammons G.J., Kadlubar F.F., Prough R.A., Martin M.V., and Guengerich F.P. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 45 (1985) 2116-2122
42. Strobl G.R., von Kruedener S., Stockigt J., Guengerich F.P., and Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J. Med. Chem. 36 (1993) 1136-1145
43. Islam S.A., Wolf C.R., Lennard M.S., and Sternberg M.J. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12 (1991) 2211-2219
44. Meyer U.A., Gut J., Kronbach T., Skoda C., Meier U.T., Catin T., and Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16 (1986) 449-464
45. Koymans L., Vermeulen N.P., van Acker S.A., te Koppele J.M., Heykants J.J., Lavrijsen K., Meuldermans W., and Donne-Op den Kelder G.M. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5 (1992) 211-219
46. Raunio H., Rautio A., Gullsten H., and Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52 (2001) 357-363
47. Lewis D.F.V., Sams C., and Loizou G.D. A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome P450 2E1. J. Biochem. Mol. Toxicol. 17 (2003) 47-52
48. Pelkonen O., Maenpaa J., Taavitsainen P., Rautio A., and Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28 (1998) 1203-1253
49. Kubinyi H. From narcosis to hyperspace: the history of QSAR. Quant. Struct.-Act. Relat. 21 (2002) 348-356
50. Kubinyi H. Quantitative structure-activity relationships in drug design. In: Ragué Schleyer V P. (Ed). Encyclopedia of Computational Chemistry (1998), Wiley, Chichester 2309-2320
51. Todeschini R., and Consonni V. Handbook of Molecular Descriptors (2000), Wiley-VCH, Weinheim
52. Bravi G., and Wikel J.H. Application of MS-WHIM descriptors: 1. Introduction of new molecular surface properties and 2. Prediction of binding affinity data. Quant. Struct.-Act. Relat. 19 (2000) 29-38
53. Bravi G., Gancia E., Mascagni P., Pegna M., Todeschini R., and Zaliani A. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: a comparative 3D QSAR study in a series of steroids. J. Comput.-Aided Mol. Des. 11 (1997) 79-92
54. Greco G., Novellino E., and Martin Y.C. Approaches to three-dimensional quantitative structure-activity relationships. Rev. Comp. Chem. 11 (1997) 183-240
55. Martin Y.C. 3D QSAR: current state, scope, and limitations. Perspect. Drug Discov. Des. 12-14 (1998) 3-23
56. Cramer III R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
57. Kubinyi H. Comparative molecular field analysis. In: Ragué Schleyer V P. (Ed). Encyclopedia of Computational Chemistry (1998), Wiley, Chichester 448-460
58. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146
59. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857
60. Cruciani G., and Watson K.A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. 37 (1994) 2589-2601
61. Pastor M., Cruciani G., McLay I., Pickett S., and Clementi S. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 43 (2000) 3233-3243
62. Cruciani G., Pastor M., and Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 11 Suppl. 2 (2000) S29-S39
63. Cruciani G., Carrupt P.A., and Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. (THEOCHEM) 503 (2000) 17-30
64. Wold S., Johansson E., and Cocchi M. PLS-partial least-squares projection to latent structures. In: Kubinyi H. (Ed). 3D-QSAR in Drug Design (1993), ESCOM Science Publishers, Leiden 523-550
65. Eriksson L., Johansson E., Lindgren F., Sjøstrøm M., and Wold S. Megavariate analysis of hierarchical QSAR data. J. Comput.-Aided Mol. Des. 16 (2002) 711-726
66. Westerhuis J.A., Kourti T., and MacGregor J.F. Analysis of multiblock and hierarchical PCA and PLS models. J. Chemometrics 12 (1998) 301-321
67. Wold S., Kettaneh N., and Tjessem K. Hierarchical multiblock PLS and PC models for easier model interpretation and as an alternative to variable selection. J. Chemometrics 10 (1996) 463-482
68. Kriegl J.M., Arnhold T., Beck B., and Fox T. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. J. Comput.-Aided Mol. Des. 19 (2005) 189-201
69. Yap C.W., and Chen Y.Z. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model. 45 (2005) 982-992
70. Molnár L., and Keserü G.M. A neural network based virtual screening of cytochrome P450 3A4 inhibitors. Bioorg. Med. Chem. Lett. 12 (2002) 419-421
71. Ekins S., Berbaum J., and Harrison R.K. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 31 (2003) 1077-1080
72. Susnow R.G., and Dixon S.L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J. Chem. Inf. Comput. Sci. 43 (2003) 1308-1315
73. Merkwirth C., Mauser H., Schulz-Gasch T., Roche O., Stahl M., and Lengauer T. Ensemble methods for classification in cheminformatics. J. Chem. Inf. Comput. Sci. 44 (2004) 1971-1978
74. Kriegl J.M., Arnhold T., Beck B., and Fox T. Prediction of human cytochrome P450 inhibition using support vector machines. QSAR Comb. Sci. 24 (2005) 491-502
75. Chohan K.K., Paine S.W., Mistry J., Barton P., and Davis A.M. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J. Med. Chem. 48 (2005) 5154-5161
76. Moon T., Chi M.H., Kim D.H., Yoon C.N., and Choi Y.S. Quantitative structure-activity relationships (QSAR) study of flavonoid derivatives for inhibition of cytochrome P450 1A2. Quant. Struct.-Act. Relat. 19 (2000) 257-263
77. O'Brien S.E., and de Groot M.J. Greater than the sum of its parts: combining models for useful ADMET prediction. J. Med. Chem. 48 (2005) 1287-1291
78. Arimoto R., Prasad M.A., and Gifford E.M. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors. J. Biomol. Screen. 10 (2005) 197-205
79. Kless A., and Eitrich T. Cytochrome P450 classification of drugs with support vector machines implementing the nearest point algorithm. Lect. Notes Comput. Sci. 3303 (2004) 191-205
80. Eitrich T., Kless A., Druska C., Meyer W., and Grotendorst J. Classification of highly unbalanced CYP450 data of drugs using cost sensitive machine learning techniques. J. Chem. Inf. Model. 47 (2007) 92-103
81. Jensen B.F., Vind C., Padkjaer S.B., Brockhoff P.B., and Refsgaard H.H. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem. 50 (2007) 501-511
82. Yap C.W., Xue Y., Li Z.R., and Chen Y.Z. Application of support vector machines to in silico prediction of cytochrome P450 enzyme substrates and inhibitors. Curr. Top. Med. Chem. 6 (2006) 1593-1607
83. Korolev D., Balakin K.V., Nikolsky Y., Kirillov E., Ivanenkov Y.A., Savchuk N.P., Ivashchenko A.A., and Nikolskaya T. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. 46 (2003) 3631-3643
84. Fox T., and Kriegl J.M. Machine learning techniques for in silico modeling of drug metabolism. Curr. Top. Med. Chem. 6 (2006) 1579-1591
85. Tropsha A., Gramatica P., and Gombar V.K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 22 (2003) 69-77
86. Eriksson L., Jaworska J., Worth A.P., Cronin M.T., McDowell R.M., and Gramatica P. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ. Health Perspect. 111 (2003) 1361-1375
87. Hawkins D.M. The problem of overfitting. J. Chem. Inf. Comput. Sci. 44 (2004) 1-12
88. Eriksson L., Arnhold T., Beck B., Fox T., Johansson E., and Kriegl J.M. Onion design and its application to a pharmaceutical QSAR problem. J. Chemometrics 18 (2004) 188-202
89. Golbraikh A., and Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J. Comput.-Aided Mol. Des. 16 (2002) 357-369
90. Wold S., Josefson M., Gottfries J., and Linusson A. The utility of multivariate design in PLS modeling. J. Chemometrics 18 (2004) 156-165
91. Sheridan R.P., Feuston B.P., Maiorov V.N., and Kearsley S.K. Similarity to molecules in the training set is a good discriminator for prediction accuracy in QSAR. J. Chem. Inf. Comput. Sci. 44 (2004) 1912-1928
92. Hansch C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metab. Rev. 1 (1972) 1-14
93. Lewis D.F.V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity and metabolism. Biochem. Pharmacol. 60 (2000) 293-306
94. Lewis D.F.V., Modi S., and Dickins M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metab. Drug Int. 18 (2001) 221-242
95. Lewis D.F.V., Jacobs M.N., and Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today 9 (2004) 530-537
96. Lewis D.F.V., and Dickins M. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab. Rev. 35 (2003) 1-18
97. Suzuki H., Kneller M.B., Rock D.A., Jones J.P., Trager W.F., and Rettie A.E. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch. Biochem. Biophys. 429 (2004) 1-15
98. Venhorst J., Onderwater R.C., Meerman J.H., Commandeur J.N., and Vermeulen N.P. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Drug Metab. Dispos. 28 (2000) 1524-1532
99. Lock R.E., Jones B.C., Smith D.A., and Hawksworth G.M. Investigation of substrate structure activity relationships (SSAR) for cytochrome P450 2C19. Br. J. Clin. Pharmacol. 45 (1998) 511P
100. Kriegl J.M., Eriksson L., Arnhold T., Beck B., Johansson E., and Fox T. Multivariate modeling of cytochrome P450 3A4 inhibition. Eur. J. Pharm. Sci. 24 (2005) 451-463
101. Haji-Momenian S., Rieger J.M., Macdonald T.L., and Brown M.L. Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorg. Med. Chem. 11 (2003) 5545-5554
102. Riley R.J., Parker A.J., Trigg S., and Manners C.N. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. 18 (2001) 652-655
103. Lewis D.F.V., and Dickins M. Substrate SARs in human P450s. Drug Discov. Today 7 (2002) 918-925
104. Lewis D.F.V., Modi S., and Dickins M. Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug. Metab. Rev. 34 (2002) 69-82
105. Lewis D.F.V. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology 11 (2003) 43-73
106. Fuhr U., Strobl G., Manaut F., Anders E.-M., Sörgel F., Lopez-de-Binas E., Chu D.T.W., Pernet A.G., and Mahr G. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. 43 (1993) 191-199
107. Iori F., da Fonseca R., Ramos M.J., and Menziani M.C. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg. Med. Chem. 13 (2005) 4366-4374
108. Lee H., Yeom H., Kim Y.G., Yoon C.N., Jin C., Choi J.S., Kim B.R., and Kim D.H. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol. 55 (1998) 1369-1375
109. Wanchana S., Yamashita F., and Hashida M. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharm. Res. 20 (2003) 1401-1408
110. Leo A., Hansch C., and Jow P.Y. Dependence of hydrophobicity of apolar molecules on their molecular volume. J. Med. Chem. 19 (1976) 611-615
111. Mao B., Gozalbes R., Barbosa F., Migeon J., Merrick S., Kamm K., Wong E., Costales C., Shi W., Wu C., and Froloff N. QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J. Chem. Inf. Model. 46 (2006) 2125-2134
112. Afzelius L., Masimirembwa C.M., Karlén A., Andersson T.B., and Zamora I. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. J. Comput.-Aided Mol. Des. 16 (2002) 443-458
113. Afzelius L., Zamora I., Masimirembwa C.M., Karlén A., Andersson T.B., Mecucci S., Baroni M., and Cruciani G. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. J. Med. Chem. 47 (2004) 907-914
114. Afzelius L., Zamora I., Ridderstrom M., Andersson T.B., Karlen A., and Masimirembwa C.M. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 59 (2001) 909-919
115. Ekins S., Bravi G., Binkley S., Gillespie J.S., Ring B.J., Wikel J.H., and Wrighton S.A. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. 28 (2000) 994-1002
116. Ekins S., Bravi G., Binkley S., Gillespie J.S., Ring B.J., Wikel J.H., and Wrighton S.A. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9 (1999) 477-489
117. Ekins S., Bravi G., Binkley S., Gillespie J.S., Ring B.J., Wikel J.H., and Wrighton S.A. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J. Pharmacol. Exp. Ther. 290 (1999) 429-438
118. Ekins S., Bravi G., Ring B.J., Gillespie T.A., Gillespie J.S., Vandenbranden M., Wrighton S.A., and Wikel J.H. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J. Pharmacol. Exp. Ther. 288 (1999) 21-29
119. Snyder R., Sangar R., Wang J., and Ekins S. Three-dimensional quantitative structure activity realtionship for CYP2D6 substrates. Quant. Struct.-Act. Relat. 21 (2002) 357-368
120. Lozano J.J., Pastor M., Cruciani G., Gaedt K., Centeno N.B., Gago F., and Sanz F. 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J. Comput.-Aided Mol. Des. 14 (2000) 341-353
121. Poso A., Juvonen R., and Gynther J. Comparative molecular field analysis of compounds with CYP2A5 binding affinity. Quant. Struct.-Act. Relat. 14 (1995) 507-511
122. Korhonen L.E., Rahnasto M., Maehoenen N.J., Wittekindt C., Poso A., Juvonen R.O., and Raunio H. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem. 48 (2005) 3808-3815
123. Poso A., Gynther J., and Juvonen R. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. J. Comput.-Aided Mol. Des. 15 (2001) 195-202
124. Rahnasto M., Raunio H., Poso A., Wittekindt C., and Juvonen R.O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 48 (2005) 440-449
125. Lesigiarska I., Pajeva I., and Yanev S. Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1. Xenobiotica 32 (2002) 1063-1077
126. Jones J.P., He M., Trager W.F., and Rettie A.E. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P450 2C9. Drug Metab. Dispos. 24 (1996) 1-6
127. Rao S., Aoyama R., Schrag M., Trager W.F., Rettie A., and Jones J.P. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J. Med. Chem. 43 (2000) 2789-2796
128. Locuson C.W., and Wahlstrom J.L. Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos. 33 (2005) 873-878
129. Locuson C.W., Rock D.A., and Jones J.P. Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 43 (2004) 6948-6958
130. Locuson C.W., Suzuki H., Rettie A.E., and Jones J.P. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J. Med. Chem. 47 (2004) 6768-6776
131. Vaz R.J., Nayeem A., Santone K., Chandrasena G., and Gavai A.V. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg. Med. Chem. Lett. 15 (2005) 3816-3820
132. Waller C.L., Evans M.V., and McKinney J.D. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. Drug Metab. Dispos. 24 (1996) 203-210
133. Golbraikh A., and Tropsha A. Beware of q2!. J. Mol. Graph. Model. 20 (2002) 269-276
134. Netzeva T.I., Worth A., Aldenberg T., Benigni R., Cronin M.T., Gramatica P., Jaworska J.S., Kahn S., Klopman G., Marchant C.A., Myatt G., Nikolova-Jeliazkova N., Patlewicz G.Y., Perkins R., Roberts D., Schultz T., Stanton D.W., van de Sandt J.J., Tong W., Veith G., and Yang C. Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern. Lab Anim. 33 (2005) 155-173
135. Norinder U. In silico modelling of ADMET-a minireview of work from 2000 to 2004. SAR QSAR Environ. Res. 6 (2005) 1-11
136. Zuegge J., Fechner U., Roche O., Parrott N.J., Engkvist O., and Schneider G. A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries. Quant. Struct.-Act. Relat. 21 (2002) 249-256
137. Masimirembwa C.M., Ridderstroem M., Zamora I., and Andersson T.B. Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates. Method. Enzymol. 357 (2002) 133-144
138. Ortiz A.R., Pisabarro M.T., Gago F., and Wade R.C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem. 38 (1995) 2681-2691
139. Boyer S., and Zamora I. New methods in predictive metabolism. J. Comput.-Aided Mol. Des. 16 (2002) 403-413
140. Zamora I., Afzelius L., and Cruciani G. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. 46 (2003) 2313-2324
141. Cruciani G., Carosati E., De Boeck B., Ethirajulu K., Mackie C., Howe T., and Vianello R. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 48 (2005) 6970-6979
142. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
143. Lewis D.F.V. Guide to Cytochromes P450 Structure and Function (2001), CRC Press, Boca Raton
144. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz de Montellano P.R. (Ed). Cytochrome P450: Structure, Mechanism, and Biochemistry (1995), Plenum Press, New York 473-535
145. Lewis D.F.V., and Dickins M. Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs). J. Enzym. Inhib. 16 (2001) 321-330